Viking Therapeutics Reports New Data from VK2735 Obesity …
2 days ago · Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024. Up to 6.8% Placebo-Adjusted Mean Weight Loss (8.2% from Baseline) After 28 Days of Dosing with Oral Tablet of VK2735. Encouraging Tolerability Through 100 mg Daily Dosing with Oral VK2735; Mild GI-Related Adverse Event Profile.
Viking Therapeutics to Highlight Clinical Data from VK2735 …
Oct 28, 2024 · VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors being developed for the potential treatment of various metabolic...
News & Events - Viking Therapeutics InvestorRoom
Feb 27, 2024 · VK2735 demonstrated encouraging safety and tolerability following 13 weeks of once-weekly dosing. Discontinuation rates in the VENTURE study were low and well-balanced among patients treated with VK2735 compared with placebo.
Viking Touts Promising Phase I Weight Loss Data for Obesity Pill ...
2 days ago · Viking Therapeutics on Sunday unveiled early data from the first-in-human study of its investigational oral obesity drug VK2735, touting strong weight loss in healthy adults and an encouraging safety profile. After 28 days of once-daily dosing, 40-mg VK2735 lowered body weight by up to 5.3% from baseline, an effect that was statistically ...
VK2735 - Viking Therapeutics
During the first quarter of 2023, Viking initiated a Phase 1 multiple ascending dose (MAD) clinical study to evaluate a novel oral formulation of VK2735. The company believes the potential to provide both a subcutaneously injected and an oral dosage form represent a significant expansion of the opportunity for VK2735.
Viking Therapeutics stock jumps after weight-loss pill shows …
2 days ago · Viking Therapeutics stock rose 5.5% in early trade Monday after the biotech posted data on its oral weight-loss drug showing better-than-expected results from a Phase 1 trial. The study of VK2735 ...
News & Events - Viking Therapeutics InvestorRoom
Mar 26, 2024 · Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for obesity demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. The company is also evaluating an oral formulation of VK2735 in a …
Viking Therapeutics Reports New Data from VK2735 Obesity …
1 day ago · SAN DIEGO - Viking Therapeutics, Inc. ('Viking') (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new clinical data from the company's VK2735 obesity program were highlighted in two poster presentations at ObesityWeek 2024, the annual meeting of the Obesity Society.
Viking Therapeutics Announces Results from Phase 1 Clinical …
Mar 26, 2024 · The 28-day MAD study results highlight positive signs of clinical activity following treatment with oral VK2735. Cohorts receiving VK2735 demonstrated dose-dependent reductions in mean body...
Viking Therapeutics Announces Positive Top-Line Results from …
Feb 27, 2024 · Patients receiving weekly doses of VK2735 demonstrated statistically significant reductions in mean body weight after 13 weeks, ranging up to 14.7% from baseline.